Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03481283 · ClinicalTrials.gov registry record
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
A clinical trial of Type 2 Diabetes and Peripheral Neuropathy, sponsored by Zabeen Mahuwala, MD.
- Recruiting
- Registry status
- 40
- Enrollment target
- 2
- Study locations
NCT03481283: Recruiting study of Type 2 Diabetes and Peripheral Neuropathy, sponsored by Zabeen Mahuwala, MD.
NCT03481283 is a study of Type 2 Diabetes and Peripheral Neuropathy that is actively recruiting participants, run by Zabeen Mahuwala, MD. The registered enrollment target is 40 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03481283, a study of Type 2 Diabetes and Peripheral Neuropathy, is actively recruiting participants, sponsored by Zabeen Mahuwala, MD.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
Three pieces of information lead to the basis for this study: 1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy. 2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes. 3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin. The purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Type-2 diabetes and the extent to which symptoms of peripheral neuropathy are expressed in those subjects. The investigators will be testing this by initially collecting blood and skin biopsy samples from subjects, followed by measuring patient sensation and pain responses to heat, cold, and pressure in the upper extremities.
Primary Outcome
RBCs will be harvested from whole blood samples of participants and quantified RBC-bound amylin will be correlated with severity of nerve conduction velocities.
Conditions Studied
Study Locations (2)
Kentucky
- UK Robert Straus Behavioral Science Laboratory - Lexington
- University of Kentucky - Kentucky Neuroscience Institute - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-02-05 |
| Est. Completion | 2029-01 |
What NCT03481283 shows while recruiting
NCT03481283 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 0 interventions.
NCT03481283 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT03481283 about?
NCT03481283 is a clinical study titled "A Causative Role for Amylin in Diabetic Peripheral Neuropathy". Three pieces of information lead to the basis for this study: 1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy. 2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes. 3. Aggregations of amylin was found in the peripheral vasculature o...
What is the current status of trial NCT03481283?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2018-02-05. Estimated completion is 2029-01.
What conditions does trial NCT03481283 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Peripheral Neuropathy.
Who is sponsoring clinical trial NCT03481283?
This trial is sponsored by Zabeen Mahuwala, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03481283 being conducted?
This trial has 2 study locations across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03481283's enrollment target sits among peer trials
40 231st of 327 higher than 88 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI